LYRM4 and central nervous system cancer: In conclusion, LYRM4-AS1 may be a potential prognostic molecular marker of poor survival in glioma, which might be associated with inflammation and immune infiltration This study provides new and promising insights for the diagnosis and treatment of glioma.